By Andrew Silver SHANGHAI (Reuters) -As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss ...

Reuters has earlier reported that two copies of Novo's weight- loss and diabetes drugs, Orsema and Fitaro, had been approved ...

As Novo Nordisk and Eli Lilly expand sales of their popular diabetes and weight-loss drugs, cheaper copies of their patented ...

The U.S. Food and Drug Administration said on Thursday there was no longer a shortage of Eli Lilly's blockbuster weight loss ...

"An MDL that encompassed any potential injury relating to use of these exceedingly popular weight loss drugs might quickly ...

Danish pharmaceutical company Novo Nordisk recently announced plans to spend approximately $1.2 billion to build a new ...

Recently published studies assert that Ozempic significantly increases the risk of developing a rare eye condition called non ...

With U.S. headquarters in Plainsboro, Novo Nordisk told NJBIZ, "NAION is a very rare eye disease, and it is not an adverse ...

Lawsuits filed in New Jersey are part of hundreds of complaints against UnitedHealthcare, PBMs, and pharmaceutical giants ...

Microsoft is highlighting learnings and strategies from some of our AI Challengers through their stories. Learn more.

This week’s pre-holiday news roundup includes a Waltham biotech’s cardiometabolic collaboration with Novo Nordisk, Akari ...

When it comes to weight loss drugs, Ozempic has become a phenomenon. With nearly $14 billion in sales in 2023, it shows no ...